- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05339126
RNS System LGS Feasibility Study
RNS System Feasibility Study of Thalamocortical Brain-Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome
To generate preliminary safety and effectiveness data for brain-responsive neurostimulation of thalamocortical networks as an adjunctive therapy in reducing the frequency of generalized seizures in individuals 12 years of age or older with Lennox Gastaut Syndrome (LGS) who are refractory to antiseizure medications.
The intent is to determine the feasibility and the optimal design of a subsequent pivotal study in order to expand the indication for use for the RNS System as a treatment for patients with medically intractable LGS.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective two-stage single-blind feasibility cross-over study designed to provide early safety and preliminary evidence of effectiveness for combined bilateral brain-responsive neurostimulation of thalamocortical networks for the treatment of generalized seizures in patients with LGS. Twenty participants will be treated with the RNS System across six Comprehensive Epilepsy Centers in the U.S. Enrollment will be staged in two cohorts of 10. Once all 10 participants of the first cohort complete Treatment Block 1 and the interim analysis criteria are met, the next cohort of 10 participants will be enrolled. The research study comprises six study periods:
- Baseline Period
- Implant (surgery)
- Post-Op Period
- Blinded Evaluation Period (which is made up of 3 treatment blocks, one of which is a sham stimulation)
- Open Label Period
- Long Term Follow-Up Period
Two neurostimulators will be placed: one in the parieto-temporal skull on the left, and the second in the homologous region on the right. Depth leads will target the bilateral CM. Cortical strip or depth leads will target the prefrontal cortex. Each neurostimulator will be connected to two ipsilateral leads: one in the prefrontal cortex and one in the CM. A total of two neurostimulators and four leads will be implanted. During the Blinded Evaluation Period, the participant will move through 3 different treatment blocks (Treatment Block1, Treatment Block 2, and Treatment Block 3) in a random order. Two of the blocks will have active stimulation treatment and one of the blocks will have no (sham) stimulation treatment. The participant and caregiver will be blinded to the treatment condition.
- Condition A - active treatment of high frequency short burst stimulation
- Condition B - active treatment of low frequency long burst stimulation
- Sham - no stimulation treatment
After completing the Blinded Evaluation Period the participant will transition to the 1-year Open Label Period and have study appointments every 3 months. After completing the 1-year Open Label Period the participant will transition to the Long Term Follow-up Period. The Long-Term Follow-up Period may last up to 2 years with appointments every 3 months until the participant complete this research or this research study ends.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Tricia Cunningham
- Phone Number: 831-854-3585
- Email: tcunningham@neuropace.com
Study Contact Backup
- Name: Julie Harvey Park
- Phone Number: 650-279-8599
- Email: jpark@neuropace.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Lindsay McCormick
- Email: lkmccormick@uabmc.edu
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of California, San Francisco
-
Contact:
- Vikram Rao, MD
- Email: Vikram.Rao@ucsf.edu
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University
-
Contact:
- Yvan Bamps
- Email: yvan.bamp@emory.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Andrew Cole
-
Contact:
- Emory Peng
- Email: epeng@mgh.harvard.edu
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Mount Sinai Hospital
-
Contact:
- Saadi Ghatan, MD
-
Contact:
- Colton Smith
- Email: Colton.Smith@mountsinai.org
-
New York, New York, United States, 10016
- Recruiting
- NYU Langone Medical Center
-
Contact:
- Daniel Friedman, MD
-
Contact:
- Jack Carter
- Email: Jack.Carter@nyulangone.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant is 15 years of age or older for first cohort; 12 years of age or older for second cohort. Note that age requirements for eligibility differ by cohort, as follows: the age limit for Cohort 1 is 15 years of age and above and the age limit for Cohort 2 may decrease to 12 years, pending a DSMB letter of recommendation, based on review of interim data analysis and concurrence with NINDS.
- Participant has medically intractable epilepsy defined as failure to achieve acceptable seizure control without unacceptable medication related side effects despite trials of 2 or more antiseizure medications.
- Participant had an average of ≥ 5 drop seizures per month in the 2 months preceding enrollment. A drop seizure is defined as an epileptic seizure (atonic, tonic, tonic-clonic, or myoclonic) involving the entire body, trunk, or head that leads or could lead to a fall, injury, or slumping in a chair.
- Participant's seizures are non-localized.
- Participant's scalp recorded EEG has features of LGS, such as multifocal spike, slow spike and wave discharges, and paroxysmal fast activity.
- Participant must (a) have a stable antiseizure medication (ASM) regimen for the 2 months preceding enrollment and (b) be willing to remain on the stable regimen, as medically able, through the Blinded Evaluation Period; rescue medication for acute seizure clusters are permitted. A stable ASM regimen is defined as no introduction or discontinuation of an ASM, and no change in an ASM dose of more than 25%.
- Participant is not on a therapeutic diet for epilepsy, or if participant is on a therapeutic diet for epilepsy must (a) have a stable diet for the 2 months preceding enrollment and (b) be willing to remain on the stable diet, as medically able, through the Blinded Evaluation Period.
- Participant does not have a vagus nerve stimulator (VNS), or if participant does have a VNS must (a) have had the VNS off for the 2 months preceding enrollment and (b) be willing to remain with the VNS off through the Blinded Evaluation Period.
- Participant is a male, or is a female of childbearing potential who is surgically sterile, 2 years postmenopausal, or practices a reliable method of contraception (hormonal, barrier method or abstention).
- Participant is willing to give informed consent (or assent, if a minor); if the participant assents or is not able to give informed consent, parent/legal guardian is willing to give informed consent.
- Participant is able to maintain a seizure log alone or with the assistance of a competent individual.
- Participant is able to attend study appointments in accordance with the study schedule.
Exclusion Criteria:
- Participant is participating in a therapeutic investigational drug or device study (including other RNS System studies).
- Participant is currently implanted with an electronic medical device that delivers electrical energy to the brain.
- Participant is currently implanted with an RNS Neurostimulator or NeuroPace Leads.
- Participant requires procedures that are contraindicated based on current RNS System labeling.
- Participant is pregnant.
- Participant has a diagnosed unstable psychiatric disorder or any attempt or expressed intent of suicide over the preceding 6 months.
- In the opinion of the investigator, the participant has a clinically significant or unstable medical condition [including alcohol, opioid, recreational cannabis (not for therapeutic purposes) or other drug use disorder] or a progressive central nervous system disease.
- Participant is taking any anticoagulants.
- In the opinion of the investigator, participant is an unsuitable candidate for this procedure.
- Participant has been diagnosed with psychogenic or non-epileptic seizures in the preceding year.
- Participant has experienced unprovoked status epilepticus in the preceding year.
- Participant has had therapeutic surgery to treat epilepsy in the preceding 3 months. Participants who have had epilepsy surgery more than 3 months prior to enrollment are eligible.
Note: For contraindications, refer to current physician labeling (manuals) for the RNS System available at the NeuroPace website (www.neuropace.com).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Condition A
high-frequency short bursts (HFSB: 100 Hz, 160 µs pulse width, 200 msec burst)
|
The RNS System provides closed loop responsive brain stimulation.
The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure.
If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
|
Active Comparator: Condition B
low-frequency long bursts (LFLB: 5 Hz, 160 µs pulse width, 5 sec burst)
|
The RNS System provides closed loop responsive brain stimulation.
The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure.
If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Annual device-related serious adverse event (SADE) rate
Time Frame: 12 months post-implant
|
The lower limit of the 95% confidence interval of the annual SADE rate at months 12 and 24 post-implant is less than 33.6% and 22.0%, respectively (twice the SADE rate of 16.8% and 11.0%, respectively, at the same time points in the RNS System pivotal study)
|
12 months post-implant
|
Safety: Annual device-related serious adverse event (SADE) rate
Time Frame: 24 months post-implant
|
The lower limit of the 95% confidence interval of the annual SADE rate at months 12 and 24 post-implant is less than 33.6% and 22.0%, respectively (twice the SADE rate of 16.8% and 11.0%, respectively, at the same time points in the RNS System pivotal study)
|
24 months post-implant
|
Effectiveness: Blinded evaluation period (BEP) responder rate
Time Frame: 12 months post-implant
|
The responder rate during one or both of the stimulation conditions (A or B) is ≥ 30%. The responder rate is the proportion of participants that are responders. A responder in this study is defined as a participant who has a ≥ 35% reduction in the frequency of drop seizures compared to that participant's pre-implant baseline. |
12 months post-implant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Post-op SAE rate
Time Frame: 4 weeks post-implant
|
The lower limit of the 95% confidence interval of the SAE rate following the implant procedure (through 4 weeks post-op) is less than 24% (twice the SAE rate of 12% at the same time point in the RNS System pivotal study).
|
4 weeks post-implant
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of SAEs of particular relevance
Time Frame: Every 12 months post-implant
|
The annual event rate of SAEs of particular relevance (device-related or not) will be calculated over time of study participation.
SAEs of particular relevance include those related to: death, erosion, infection, suicidality, depression, hemorrhage, seizure-related injury, and tolerability of stimulation
|
Every 12 months post-implant
|
Affective status
Time Frame: Implant through 4 years post-implant
|
Affective status (by summary scores from the Beck Depression Inventory, either the BDI-II or BYI-II, depending on age at time of the initial clinic appointment) will be described for the pre-implant baseline, as well as at the transition to Treatment Block 1, Treatment Block 2, Treatment Block 3, and Open Label; and for every 6 months thereafter that the participant is in the study.
|
Implant through 4 years post-implant
|
Cognitive function
Time Frame: Implant through 2 years post-implant
|
Neuropsychological functioning as assessed by neuropsychological testing with validated, standardized inventories to assess domains that include attention (Flanker Inhibitory Control and Attention Test).
The inventory is taken from the NIH Toolbox Cognition Battery and will be described by presenting summary scores for the pre-implant baseline, as well as for the end of the Blinded Evaluation Period and for the end of the Open Label Period.
|
Implant through 2 years post-implant
|
Cognitive function
Time Frame: Implant through 2 years post-implant
|
Neuropsychological functioning as assessed by neuropsychological testing with validated, standardized inventories to assess three domains that include memory (Picture Sequence Memory Test).
The inventory is taken from the NIH Toolbox Cognition Battery and will be described by presenting summary scores for the pre-implant baseline, as well as for the end of the Blinded Evaluation Period and for the end of the Open Label Period.
|
Implant through 2 years post-implant
|
Cognitive function
Time Frame: Implant through 2 years post-implant
|
Neuropsychological functioning as assessed by neuropsychological testing with validated, standardized inventories to assess three domains that include vocabulary (Picture Vocabulary Test).
The inventory is taken from the NIH Toolbox Cognition Battery and will be described by presenting summary scores for the pre-implant baseline, as well as for the end of the Blinded Evaluation Period and for the end of the Open Label Period.
|
Implant through 2 years post-implant
|
Median percent change in seizure counts
Time Frame: Implant through 4 years post-implant
|
Median percentage change in counts of:
|
Implant through 4 years post-implant
|
Days with seizures
Time Frame: Implant through 4 years post-implant
|
Days with:
A non-drop seizure is defined as an absence seizure, a myoclonic seizure, or an atonic or tonic seizure not leading to a fall. |
Implant through 4 years post-implant
|
Participant quality of life as measured by the QOLIE-AD-48
Time Frame: Implant through 4 years post-implant
|
Quality of life for the pre-implant baseline, as well as at the transitions to Treatment Block 1, Treatment Block 2, Treatment Block 3, and Open Label; and for every 6 months thereafter that the participant is in the study according to the QOLIE-AD-48 (validated for ages 12-17 years, depending on age at time of assessment).
|
Implant through 4 years post-implant
|
Participant quality of life as measured by the QOLIE-31-P
Time Frame: Implant through 4 years post-implant
|
Quality of life for the pre-implant baseline, as well as at the transitions to Treatment Block 1, Treatment Block 2, Treatment Block 3, and Open Label; and for every 6 months thereafter that the participant is in the study, according to the QOLIE-31-P (validated for ages 18 and older, depending on age at time of assessment).
|
Implant through 4 years post-implant
|
Caregiver burden
Time Frame: Implant through 4 years post-implant
|
Caregiver burden for the pre-implant baseline, as well as at the transitions to Treatment Block 1, Treatment Block 2, Treatment Block 3, and Open Label; and for every 6 months thereafter that the participant is in the study, according to the following scales: • Modified Caregiver Strain Index (MCSI) |
Implant through 4 years post-implant
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Martha Morrell, MD, NeuroPace, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NP10015
- UH3NS109557 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The following data types will be uploaded to the Data Archive for the BRAIN Initiative (DABI):
- Medical imaging: MRI, CT
- Neurophysiological recordings: intracranial EEG recordings
- Data collected from RNS Neurostimulator, reformatted for analysis.
- Clinical Trial Outcome and Endpoint data.
- Treatment condition status for subjects.
Data will be uploaded every 6 months. Access is restricted and must be requested.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on RNS System
-
NeuroPaceRecruitingEpilepsy | Drug Resistant Epilepsy | Focal Epilepsy | Partial Seizure | Neurostimulator; ComplicationsUnited States
-
Medical College of WisconsinNot yet recruitingGlioma | Brain Cancer | Brain Tumor | Glioma Intracranial | Gliomas Benign | Motor Cortex; Lesion
-
VA Greater Los Angeles Healthcare SystemUniversity of California, Los AngelesRecruitingPost-Traumatic Stress DisorderUnited States
-
Baylor College of MedicineRecruiting
-
Diagram B.V.TerminatedArrhythmias, CardiacNetherlands
-
The University of Texas Health Science Center,...Recruiting